Improvement of survival and insulin function of islet grafts in diabetic rats by co-transplantation of adipose tissue-derived mesenchymal stem cells
Publish place: 1st International Iranian Tissue Engineering and Regenerative Medicine Congress (ITERM2018)
Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 333
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ITERMED01_227
تاریخ نمایه سازی: 7 مرداد 1398
Abstract:
Pancreatic islet transplantation is a commonly therapeutic strategy for type 1 diabetes mellitus (T1DM). However, it has been hindered by the shortage of available donor organs, that spurs research into alternative means of β-cells from stem cells. Recent reports have demonstrated that co-culture and co-transplantation of pancreatic islets with stem cells, preserve and improve islet mass and quality by increasing islet function in vitro and greater graft viability, function and longevity in vivo, suggesting possibilities for relevant clinical trials to be carried out. On such a basis, this study was designed to determine the effects of hybrid islet transplantation with adipose tissue-derived mesenchymal stem cells (AT-MSCs) on the survival and insulin function of allogeneic islet graft in a diabetic rat. Different numbers of islets either alone or with AT-MSCs were transplanted simultaneously into omental pouch in a rat model of streptozotocin (STZ)-induced diabetes. Our findings provide evidence that AT-MSCs are suitable for creating a microenvironment favorable for the repair and longevity of pancreatic islet β-cells, exerting their effects through various mechanisms including: i) contribution to insulin production through a differentiation-associated process; ii) preservation of islet morphology; iii) restoration of islet function; iv) secretion of anti-inflammatory and immunoregulatory factors (cytokines); v) enhancement of islet revascularization. In conclusion, we propose that AT-MSCs as a secondary cell source may be best used in both islet co-culture and co-transplantation strategies to limit the mass of donor islet materials, which currently delimitates the broader application of allogenic islet transplantation as a therapy for T1DM
Keywords:
Authors
Mona Navaei-Nigjeh
Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
Nasrin Lotfibakhshayesh
Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
Masoud Solimani
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Mohammad abdollahi
Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences, Tehran University of Medical Science, Tehran, Iran